NEW YORK, June 19 - Three weeks after announcing its proposed acquisition of Gemini Genomics, Sequenom provided additional details Tuesday about the combined company's business strategy and financial projections.

In May, San Diego-based Sequenom said that it had agreed to acquire clinical genomics company Gemini Genomics, of Cambridge, UK, for $238 million in stock in an effort to boost the company's drug development and clinical capabilities. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.